Navarixin is primarily used in research settings as a selective antagonist of the CXCR2 receptor, which plays a role in inflammatory responses. It is investigated for its potential to modulate immune cell migration, particularly neutrophils, making it useful in studies related to chronic inflammation, autoimmune diseases, and cancer. In oncology research, Navarixin has been explored to understand how blocking CXCR2 can reduce tumor growth and metastasis by affecting the tumor microenvironment. It is also studied in respiratory diseases such as COPD and asthma, where neutrophil infiltration contributes to tissue damage. Its application remains largely experimental, supporting drug development and mechanistic studies in immunology and cancer biology.